Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years

被引：0
|
作者：
Horinouchi, H. [1 ]
Ohe, Y. [1 ]
Yamanaka, Y. [2 ]
Kurata, T. [2 ]
Watanabe, K. [3 ]
Hosomi, Y. [3 ]
Nakahara, Y. [4 ]
Asao, T. [5 ]
Saeki, S. [6 ]
Tsubata, Y. [7 ]
Fujita, Y. [8 ]
Konishi, J. S. [9 ]
Mizugaki, H. [10 ]
Ohuchi, M. [11 ]
Yagishita, S. [11 ]
Hamada, A. [11 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Kansai Med Univ Hosp, Osaka, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[4] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan
[5] Juntendo Univ Hosp, Tokyo, Japan
[6] Kumamoto Univ Hosp, Kumamoto, Japan
[7] Shimane Univ, Fac Med, Matsue, Shimane, Japan
[8] Jikei Univ, Sch Med, Tokyo, Japan
[9] Hokkaido Univ, Fac Med, Sapporo, Hokkaido, Japan
[10] JFCR, Canc Inst Hosp, Tokyo, Japan
[11] Natl Canc Ctr, Res Inst, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Pembrolizumab; pharmacokinetics; Elderly;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP11.03-08
引用
收藏
页码：S622 / S622
页数：1
相关论文
共 50 条
  • [41] Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment
    Sirgi, Yasmina
    Krochmal, Rebecca
    Fleury, Christine M.
    Holmes, Margaret
    Dewitt, Christine A.
    Cardis, Michael
    Kim, Chul
    CLINICAL LUNG CANCER, 2022, 23 (06) : 542 - 546
  • [42] Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient
    Matsumoto, Sachiko
    Watanabe, Keisuke
    Kobayashi, Nobuaki
    Irie, Kuniyasu
    Yamanaka, Shoji
    Kaneko, Takeshi
    RESPIROLOGY CASE REPORTS, 2020, 8 (05):
  • [43] Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer
    Muchnik, Eugene
    Loh, Kah Poh
    Strawderman, Myla
    Magnuson, Allison
    Mohile, Supriya G.
    Estrah, Vered
    Maggiore, Ronald J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2019, 67 (05) : 905 - 912
  • [44] New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
    Bylicki, Olivier
    Paleiron, Nicolas
    Rousseau-Bussac, Gaelle
    Chouaid, Christos
    ONCOTARGETS AND THERAPY, 2018, 11 : 4051 - 4064
  • [45] Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer
    Poma, Anello Marcello
    Bruno, Rossella
    Pietrini, Iacopo
    Ali, Greta
    Pasquini, Giulia
    Proietti, Agnese
    Vasile, Enrico
    Cappelli, Sabrina
    Chella, Antonio
    Fontanini, Gabriella
    CANCERS, 2021, 13 (15)
  • [46] Checkpoint inhibitors in older patients with advanced non-small cell lung cancer
    Reale, Maria Lucia
    Romano, Gianpiero Diego
    Paolelli, Loretta
    Leo, Silvana
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 188
  • [47] Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial
    Matsumoto, Hiromi
    Kobayashi, Nobuaki
    Somekawa, Kohei
    Fukuda, Nobuhiko
    Kaneko, Ayami
    Kamimaki, Chisato
    Kubo, Sousuke
    Tanaka, Katsushi
    Tagami, Yoichi
    Teranishi, Shuhei
    Watanabe, Keisuke
    Horita, Nobuyuki
    Hara, Yu
    Yamamoto, Masaki
    Kudo, Makoto
    Koizumi, Harumi
    Miura, Kenji
    Miyazawa, Naoki
    Kaneko, Takeshi
    THORACIC CANCER, 2022, 13 (02) : 228 - 235
  • [48] Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: A prospective population-based study
    Wanders, Rinus
    Steevens, Jessie
    Botterweck, Anita
    Dingemans, Anne-Marie C.
    Reymen, Bart
    van Baardwijk, Angela
    Borger, Jacques
    Bootsma, Gerben
    Pitz, Cordula
    Lunde, Ragnar
    Geraedts, Wiel
    Lambin, Philippe
    De Ruysscher, Dirk
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (18) : 2691 - 2697
  • [49] Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial
    Wang, Na
    Zheng, Lie
    Li, Meichen
    Hou, Xue
    Zhang, Baishen
    Chen, Jing
    Li, Su
    Chen, Likun
    LUNG CANCER, 2023, 178 : 183 - 190
  • [50] Major clinical benefit from adjuvant chemotherapy for stage II-III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis
    Blasi, Miriam
    Eichhorn, Martin E.
    Christopoulos, Petros
    Winter, Hauke
    Heussel, Claus Peter
    Herth, Felix J.
    El Shafie, Rami
    Kriegsmann, Katharina
    Kriegsmann, Mark
    Stenzinger, Albrecht
    Bischoff, Helge
    Thomas, Michael
    Kuon, Jonas
    BMC PULMONARY MEDICINE, 2022, 22 (01)
12345